Veracyte Analyst Ratings
Analyst Issues Sell Rating for Veracyte Amidst Strong Q2 Growth but Limited Near-Term Upside
CRISPR Therapeutics Analyst Ratings
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
Intellia Therapeutics Analyst Ratings
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Buy Rating Affirmed for 10x Genomics Amidst Strategic Realignment and Promising Growth Prospects
Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)
Strategic Merger and Financial Prospects Affirm Buy Rating for Recursion Pharmaceuticals
Veracyte (VCYT) Receives a Buy From Scotiabank
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk
Recursion Pharmaceuticals Analyst Ratings
Maintaining Hold: Balancing 10x Genomics' Growth Prospects With Economic and Strategic Challenges
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Veracyte's Growth Momentum and Robust Test Adoption Fuel Buy Rating
Barclays Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
10x Genomics (TXG) Receives a Buy From Barclays